Growth hormone (GH) transduction defect (GHTD) is a growth disorder with impaired signal transducer and activator of transcription 3 (STAT3) phosphorylation mediated by overexpression of cytokine-inducible SH2-containing protein (CIS), which causes increased growth hormone receptor (GHR) degradation. This study investigated the role of epidermal growth factor (EGF) in the restoration of normal GH signaling in GHTD.
Protein expression, cellular localization and physical contact of proteins of the GH and EGF signaling pathways were studied by Western immunoblotting, immunofluorescence and co-immunoprecipitation, respectively. These were performed in fibroblasts of one GHTD patient (P) and one control child (C) at the basal state and after induction with human GH (hGH) 200 μg/L (GH200), either with or without silencing of CIS mRNA, and after induction with hGH 1000 μg/L (GH1000) or 50 ng/mL EGF.
The membrane availability of the EGF receptor (EGFR) and the activated EGFR (pEGFR) was increased in P only after simultaneous GH200 and silencing of CIS mRNA or with GH1000, whereas this occurred in C after GH200 alone. After EGF induction, the membrane localization of GHR, STAT3 and that of EGFR were increased in P more than in C.
In conclusion, in GHTD, the EGFR seems to participate in successful GH signaling, but induction of GHTD fibroblasts with a higher dose of hGH is needed. The EGF/EGFR pathway, in contrast to the GH/GHR pathway, seems to function normally in P and is more primed compared to C. The involvement of the EGFR in successful GH signaling may explain the catch-up growth seen in the Ps when exogenous hGH is administered.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science 1982;216:1237–9.Search in Google Scholar
2. Isgaard J, Nilsson A, Lindahl A, Jansson JO, Isaksson OG. Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats. Am J Physiol 1986;250:E367–72.Search in Google Scholar
3. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987;8:115–31.Search in Google Scholar
4. Kim SO, Loesch K, Wang X, Jiang J, Mei L, et al. A Role for Grb2-associated binder-1 in growth hormone signaling. Endocrinology 2002;143:4856–67.Search in Google Scholar
5. Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, et al. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol 1996;10:519–33.Search in Google Scholar
6. Kim SO, Jiang J, Yi W, Fengi GS, Frank SJ. Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signalling. J Biol Chem 1998;4:2344–54.Search in Google Scholar
7. Yoshimura A. The CIS family. Negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev 1998;9:197–204.Search in Google Scholar
8. Leung DW, Spencer SA, Cachlanes G, Hammonds RG, Collins C, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987;330:537–43.Search in Google Scholar
9. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J 1996;15:3806–12.Search in Google Scholar
10. Landsman T, Waxman DJ. Role of the cytokine-induced SH2-containing protein CIS in growth hormone receptor internalization. J Biol Chem 2005;280:37471–80.Search in Google Scholar
11. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 1997;390:91–6.Search in Google Scholar
12. Kim SO, Houtman JC, Jiang J, Ruppert JM, Bertics PJ, et al. Growth hormone-induced alteration in ErbB-2 phosphorylation status in 3T3–F442A fibroblasts. J Biol Chem 1999;274:36015–24.Search in Google Scholar
13. Huang Y, Kim SO, Jiang J, Frank SJ. Growth hormone-induced phosphorylation of EGF receptor in 3T3–F442A cells: modulation of EGF-induced trafficking and signaling. J Biol Chem 2003;278:18902–13.Search in Google Scholar
14. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139–47.Search in Google Scholar
15. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, et al. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006;91:1826–31.Search in Google Scholar
16. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363–7.Search in Google Scholar
17. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211–22.Search in Google Scholar
18. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, et al. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128–34.Search in Google Scholar
19. Rojas-Gil AP, Ziros PG, Diaz L, Kletsas D, Basdra EK, et al. Growth hormone/JAK-STAT axis signal-transduction defect. FEBS J 2006;273:3454–66.Search in Google Scholar
20. Rojas Gil AP, Kostopoulou E, Karageorgou I, Kamzelas K, Spiliotis BE. Increased growth hormone receptor (GHR) degradation due to over-expression of cytokine inducible SH2 domain-containing protein (CIS) as a cause of GH transduction defect (GHTD). J Pediatr Endocr Met 2012;25:897–908.Search in Google Scholar
21. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006;18:2089–97.Search in Google Scholar
22. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2–16.Search in Google Scholar
23. Ram PA, Waxman DJ. Role of the Cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 2000;275:39487–96.Search in Google Scholar
24. Kario E, Marmor MD, Adamsky K, Citri A, Amit I, et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. JBC 2005;280:7038–48.Search in Google Scholar
25. Tonko-Geymayer S, Goupille O, Tonko M, Soratrol C, Yoshimura A, et al. Regulation and function of the cytokine-inducible SH-2 domain proteins, CIS and SOCS3, in mammary epithelial cells. Mol Endocrinol 2002;16:1680–95.Search in Google Scholar
©2017 Walter de Gruyter GmbH, Berlin/Boston